Eloxx Pharmaceuticals, INC Schedule 13G passive stakes

Samsara BioCapital entities and Srinivas Akkaraju have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Eloxx Pharmaceuticals' common stock.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed beneficial ownership of 400,000 shares, representing 9.91% of Eloxx Pharmaceuticals' common stock as of June 30, 2026.

Aberdeen Group plc and abrdn Inc. have jointly reported beneficial ownership of 9.91% of Eloxx Pharmaceuticals Inc. common stock as of June 30, 2026.

Coastlands Capital LP and affiliates have reported a 9.99% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. through common stock and pre-funded warrants.

Domicilium Capital Partners and associated entities have filed a Schedule 13G reporting a 19.99% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

EcoR1 Capital, LLC and Oleg Nodelman have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

Stonepine Capital Management has reported a 9.9% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. following a recent offering.

Investment entities led by Raymond Debbane have reported a 9.99% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. as of June 9, 2026.

Investment firm Domicilium Capital Partners and affiliates report a 4.9% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

Coastlands Capital LP and its affiliates have filed an exit statement after reducing their beneficial ownership in Eloxx Pharmaceuticals to 4.99%.

Investment firm Domicilium Capital Partners and Daniel Simon have reported an 18.6% beneficial ownership stake in Eloxx Pharmaceuticals, Inc.

Coastlands Capital LP and its affiliates have disclosed a significant 16.51% passive ownership stake in Eloxx Pharmaceuticals following the exercise of pre-funded warrants.